These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Thyroid Ultrasonography in Differentiation between Graves' Disease and Hashimoto's Thyroiditis. Pishdad P; Pishdad GR; Tavanaa S; Pishdad R; Jalli R J Biomed Phys Eng; 2017 Mar; 7(1):21-26. PubMed ID: 28451576 [TBL] [Abstract][Full Text] [Related]
44. Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases. Watanabe M; Amino N; Hochito K; Watanabe K; Kuma K; Iwatani Y Thyroid; 1997 Oct; 7(5):743-7. PubMed ID: 9349577 [TBL] [Abstract][Full Text] [Related]
45. [Differentiated thyroid carcinoma in previously manifested autoimmune thyroid disease]. Cirić J; Beleslin-Nedeljković B Srp Arh Celok Lek; 2005 Oct; 133 Suppl 1():74-6. PubMed ID: 16405261 [TBL] [Abstract][Full Text] [Related]
46. Adaptation and validation of the Hungarian version of Thyroid-Related Patient-Reported Outcome-39 (ThyPro-39) questionnaire: testing factor structure, known-group validity with the comparison of quality of life in Hashimoto's thyroiditis and Graves' disease. Rigó A; Malkov K; Szabó A; Bognár VK; Urbán R J Patient Rep Outcomes; 2023 Jun; 7(1):60. PubMed ID: 37368126 [TBL] [Abstract][Full Text] [Related]
47. [What is the role of allergic sensitization in Graves' disease?]. Molnár I Orv Hetil; 2007 Jul; 148(29):1347-52. PubMed ID: 17631469 [TBL] [Abstract][Full Text] [Related]
48. Endothelin-1 levels in patients with disorders of the thyroid gland. Tilly N; Schneider JG; Leidig-Bruckner G; Sommer U; Kasperk C Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):80-4. PubMed ID: 12746758 [TBL] [Abstract][Full Text] [Related]
49. Risk factors associated with benign and malignant thyroid nodules in autoimmune thyroid diseases. Lima PC; Moura Neto A; Tambascia MA; Zantut Wittmann DE ISRN Endocrinol; 2013; 2013():673146. PubMed ID: 23762596 [TBL] [Abstract][Full Text] [Related]
50. Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' disease. Bogner U; Schleusener H; Wall JR J Clin Endocrinol Metab; 1984 Oct; 59(4):734-8. PubMed ID: 6548225 [TBL] [Abstract][Full Text] [Related]
51. Normal immunoregulation of in vitro antibody secretion in autoimmune thyroid disease. MacLean DB; Miller KB; Brown R; Reichlin S J Clin Endocrinol Metab; 1981 Oct; 53(4):801-5. PubMed ID: 6457056 [TBL] [Abstract][Full Text] [Related]
53. HLA-DQB1-associated susceptibility that distinguishes Hashimoto's thyroiditis from Graves' disease in type I diabetic patients. Santamaria P; Barbosa JJ; Lindstrom AL; Lemke TA; Goetz FC; Rich SS J Clin Endocrinol Metab; 1994 Apr; 78(4):878-83. PubMed ID: 8157715 [TBL] [Abstract][Full Text] [Related]
54. A differential association of interferon-gamma high-producing allele T and low-producing allele A (+874 A/T) with Hashimoto's thyroiditis and Graves' disease. Rekha PL; Ishaq M; Valluri V Scand J Immunol; 2006 Oct; 64(4):438-43. PubMed ID: 16970687 [TBL] [Abstract][Full Text] [Related]
55. Activated (Ia+) T-lymphocytes and their subsets in autoimmune thyroid diseases: analysis by dual laser flow microfluorocytometry. Chan JY; Walfish PG J Clin Endocrinol Metab; 1986 Feb; 62(2):403-9. PubMed ID: 3484483 [TBL] [Abstract][Full Text] [Related]